News

June 15, 2020June 15, 2020

Cancer Vaccine Plus Adoptive T-cell Therapy Placed on Fast Track

News

TVI-Brain-1, an immunotherapy being developed by TVAX Biomedical, was given fast track designation by the U.S. Food and Drug Administration (FDA) as a potential treatment of glioblastoma multiforme, a deadly form ... Read more

June 12, 2020June 12, 2020

FDA Approves Opdivo for Advanced Esophageal Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the treatment of people with advanced, inoperable, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) previously treated ... Read more

June 5, 2020June 5, 2020

Tislelizumab-Chemo Combo Does Well in Advanced Squamous NSCLC Trial

News

Adding Beigene‘s experimental therapy tislelizumab to standard first-line chemotherapy significantly delays disease progression or death in patients with advanced squamous non-small cell lung cancer (NSCLC), data from a Phase ... Read more

June 3, 2020June 3, 2020

FDA Approves Tecentriq-Avastin Combo for Newly Diagnosed Advanced Liver Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of newly diagnosed patients with advanced hepatocellular carcinoma (HCC), the ... Read more

June 1, 2020June 1, 2020

Surface, Merck Partner on SRF617-Keytruda Combo Targeting Solid Tumors

News

Surface Oncology has entered a collaboration with Merck to investigate a combination of SRF617 and Keytruda (pembrolizumab) in patients with solid tumors, with a particular focus on individuals with ... Read more

May 26, 2020May 26, 2020

ONCOS-102 Plus Chemo Showing Sustained Benefit in Mesothelioma Trial

News

A combination of ONCOS-102 plus standard chemotherapy continues to extend the time without disease progression and appears to induce immune system activity in people with malignant pleural mesothelioma unable ... Read more

May 20, 2020May 20, 2020

FDA Approves Tecentriq as Initial Treatment for Advanced NSCLC

News

The U.S. Food and Drug Administration (FDA) has approved Genentech‘s Tecentriq (atezolizumab) as an initial treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors produce high levels of ... Read more

May 19, 2020May 19, 2020

FDA Approves Opdivo-Yervoy Combo for First-line Treatment of Advanced NSCLC

News

The U.S. Food and Drug Administration (FDA) has approved a combination of Opdivo (nivolumab) with low-dose Yervoy (ipilimumab) for the initial treatment of people with metastatic non-small cell lung ... Read more

May 12, 2020May 12, 2020

ICT’s CAR T-cell Therapy Shows Promise in Reducing Size of Solid Tumors

News

A potential CAR T-cell therapy by Innovative Cellular Therapeutics (ICT) showed early signs of safety and efficacy, significantly reducing tumor size in four patients with thyroid or colorectal cancer, new ... Read more

May 5, 2020May 5, 2020

Dostarlimab Shows Promise for Advanced Endometrial Cancer, Early Trial Results Show

News

A subset of women with recurrent or advanced endometrial cancer, whose disease progressed on or after platinum-based chemotherapy, achieved clinically meaningful responses after treatment with dostarlimab, results of a ... Read more

Pin It on Pinterest